Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Recurrent Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects
- The report assesses Recurrent Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Accendatech Co LtdAdlai Nortye Biopharma Co Ltd
Advanced Accelerator Applications SA
Alaunos Therapeutics Inc
AngioChem Inc
Apogenix AG
Arcus Biosciences Inc
Ariceum Therapeutics GmbH
Arog Pharmaceuticals Inc
Ascletis Pharma Inc
AstraZeneca Plc
Aucentra Therapeutics Pty Ltd
Aveta Biomics Inc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Beijing DCTY Biotech Co Ltd
Beijing Pearl Biotechnology LLC
Beijing Sanbo Brain Hospital
Beijing Tiantan Affiliated Hospital
BerGenBio ASA
Bexion Pharmaceuticals Inc
BeyondBio Inc
Bio-Thera Solutions Ltd
Biocon Ltd
Biodexa Pharmaceuticals PLC
Biohaven Ltd
Black Diamond Therapeutics Inc
Boehringer Ingelheim International GmbH
BoYuan RunSheng Pharma Hangzhou Co Ltd
Bristol-Myers Squibb Co
Candel Therapeutics Inc
CHA Biotech Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
CNS Pharmaceuticals Inc
Crimson BioPharm Inc
Cytea Bio
Cyteph Pty Ltd
Daiichi Sankyo Co Ltd
DNAtrix Inc
Duke University
Duke University Medical Center
Eisai Co Ltd
Elevar Therapeutics Inc
Eli Lilly and Co
Endeavour College of Natural Health
Enterome Bioscience SA
Epygen Biotech Pvt Ltd
Erasca Inc
ERC Belgium SA
Eydis Bio Inc
F. Hoffmann-La Roche Ltd
Gan & Lee Pharmaceuticals Co Ltd
Genexine Inc
Graduate School of Cancer Science and Policy
GSK plc
Guangdong 999 Brain Hospital
Henry Ford Health System
Huashan Hospital
ImmunityBio Inc
Immunomet Therapeutics Inc
Immvira Co Ltd
IN8bio Inc
Incyte Corp
Istari Oncology Inc
iXgene Inc
Jecho Biopharmaceuticals Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kadmon Holdings Inc
Kairos Pharma Ltd
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kite Pharma Inc
Komipharm International Co Ltd
Lixte Biotechnology Holdings Inc
Lumos Pharma Inc
Marino Biotechnology Co Ltd
Massachusetts General Hospital
Matrix Biomed Inc
Mayo Clinic
Medicenna Therapeutics Corp
MediciNova Inc
Merck & Co Inc
Merck KGaA
MimiVax LLC
Molecular Templates Inc
Mustang Bio Inc
NanoPharmaceuticals LLC
Neonc Technologies Inc
Nerviano Medical Sciences SRL
Neurosurgical Research Foundation
New York University
Northwestern University
Novartis AG
Oblato Inc
OncoTherapy Science Inc
Oryx GmbH & Co KG
OX2 Therapeutics Inc
Pfizer Inc
Photolitec LLC
Plus Therapeutics Inc
Polaris Pharmaceuticals Inc
Potenza Therapeutics Inc
Prelude Therapeutics Inc
Prestige BioPharma Ltd
Regeneron Pharmaceuticals Inc
Revolution Medicines Inc
Royan Institute
Shanghai Simnova Biotechnology Co Ltd
Shanghai Yuansong Biotechnology Co Ltd
Shenzhen Geno-Immune Medical Institute
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
Simcere Pharmaceutical Group Ltd
SonALASense Inc
Stanford University
Starlight Therapeutics Inc
Stemline Therapeutics Inc
Sumitomo Pharma Co Ltd
Suzhou Neupharma Co Ltd
Synermore Biologics Co Ltd
Taiho Oncology Inc
TargTex SA
Tasly Pharmaceutical Group Co Ltd
TheraBiologics Inc
Therapeia GmbH & Co KG
TRACON Pharmaceuticals Inc
Transgene SA
TVAX Biomedical Inc
UAB Minority Health and Health Equity Research Center
UCLAs Jonsson Comprehensive Cancer Center
University of North Carolina at Chapel Hill
University of Texas MD Anderson Cancer Center
Vaximm AG
VBI Vaccines Inc
Verastem Inc
Vigeo Therapeutics Inc
WPD Pharmaceuticals Inc
Xi'An Yufan Biotechnology Co Ltd
Xijing Hospital
Zai Lab Ltd